English | 繁體

Search in the results

UM

Browse/Search Results:  1-3 of 3 Help

Selected(0)Clear Items/Page:    Sort:
Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer Journal article
Lou, Linlin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Mo, Jianshan, Yan, Jiayu, Gong, Xiaoxiao, Liu, Guopin, Lu, Jinjian, Yue, Peibin, Zhang, Kai, Zhang, Jian, Wang, Yan Dong, Zhang, Xiao Lei. Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer[J]. Journal of Experimental and Clinical Cancer Research, 2025, 44(1), 6.
Authors:  Lou, Linlin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen;  Mo, Jianshan; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date：2025/01/22
Small Cell Lung Cancer  Liver Metastasis  Hepatic Stellate Cells  Postn  Tumor Microenvironment  
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia Journal article
Mo, Jianshan, Deng, Lin, Peng, Keren, Ouyang, Shumin, Ding, Wen, Lou, Linlin, Lin, Ziyou, Zhu, Jianzheng, Li, Jingwei, Zhang, Qiyi, Wang, Pengyan, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Lu, Jin Jian, Zhu, Kai, Zheng, Yongjiang, Wang, Yuanxiang, Zhang, Xiaolei. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia[J]. Journal of Hematology & Oncology, 2023, 16(1), 15.
Authors:  Mo, Jianshan;  Deng, Lin;  Peng, Keren;  Ouyang, Shumin;  Ding, Wen; et al.
Favorite | TC[WOS]:20 TC[Scopus]:19  IF:29.5/26.9 | Submit date：2023/03/06
Aml  Immunotherapy  Stat3 Inhibitor  Vista  
Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer Journal article
Lu, Jiaye, Li, Jingwei, Lin, Ziyou, Li, Huaxuan, Lou, Linlin, Ding, Wen, Ouyang, Shumin, Wu, Yonghui, Wen, Yuanzhen, Chen, Xiaobing, Yue, Peibin, Wang, Yuanxiang, Liu, Peiqing, Lu, Jinjian, Zhang, Jian, Feng, Weineng, Zhang, Xiaolei. Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer[J]. Cancer Letters, 2023, 564, 216205.
Authors:  Lu, Jiaye;  Li, Jingwei;  Lin, Ziyou;  Li, Huaxuan;  Lou, Linlin; et al.
Favorite | TC[WOS]:31 TC[Scopus]:31  IF:9.1/8.3 | Submit date：2023/07/20
Acquired Tki Resistance  Cd47  Lung Cancer  Stat3  Tams